In conclusion, this study used network pharmacology and computer simulation of molecular docking to demonstrate that the active ingredients of Polygonatum, such as beta-sitosterol, baicalein, and liquiritigenin, exert their therapeutic efficacy in treating Alzheimer’s disease by acting on targets such as AKT1, TP53, CASP3, JUN, STAT3, and others. Here, AKT1 is linked to early-onset autosomal dominant Alzheimer disease.